Pangenomic rolls out Agenta Health e-commerce site

Executive Summary

• Pangenomic Health Inc. launched "Agenta Health," a new e-commerce platform serving as a key component of its NaraCare.AI strategy, aimed at providing personalized alternative health products and evidence-based information.
• The company provided an update on the exercise of 7.5 million share purchase warrants issued in January 2025, noting that approximately 6.68 million warrants have been exercised to date.
• Proceeds from the warrant exercises total $867,932, which the company intends to use for general corporate and working capital purposes.

Key Details

• Agenta Health Platform Launch:
  • Launched as a new e-commerce shopping site.
  • Described as the "springboard" for the NaraCare.AI platform strategy.
  • Offers a unique line of products supporting a holistic approach to health and wellness.
  • Will incorporate evidence-based information regarding benefits, dosage use, adverse effects, and drug interactions.
  • Full rollout of the NaraCare.AI platform is scheduled for the fourth quarter of 2025.
• Warrant Financing Update:
  • Original Issuance: 7.5 million share purchase warrants issued on or about January 10, 2025.
  • Exercise Price: $0.13 per share.
  • Expiration Date: August 25, 2025.
  • Exercises to Date: 6,676,406 warrants exercised.
  • Total Proceeds: $867,932.
  • Use of Proceeds: General corporate and working capital purposes.

Notable Quotes

• "The Agenta Health e-commerce site is the springboard for our NaraCare.AI platform," said Maryam Marissen, president and chief executive officer of Pangenomic Health. "We believe consumers are missing personalized on-line shopping experiences for alternative health products, and are looking for better information about products that fit their unique health situation, lifestyle and personal goals."